Safety of office-based percutaneous injection laryngoplasty with calcium hydroxylapatite

Minhyung Lee, Doh Young Lee, Tack-Kyun Kwon

Research output: Contribution to journalReview articleResearchpeer-review

Abstract

Objective: To evaluate the safety of office-based calcium hydroxylapatite (CaHA) injection laryngoplasty via the cricothyroid approach through an analysis of all procedures performed over a period of 10 years at a single institution. Methods: In total, 962 office-based CaHA injection laryngoplasty via the cricothyroid approach procedures were performed by a single physician at our institution between 2007 and 2016. From these, 955 procedures performed in 617 patients were included in our analysis. The medical records of all 617 patients were retrospectively reviewed. We classified all procedure-related complications according to the time of onset. Complications that occurred during the procedure were considered intraprocedural complications, whereas complications that developed within 1 week after injection and those that developed after 1 week and were recorded more than twice in the medical records were considered acute and delayed complications, respectively. Failed cases were categorized separately as failure. Results: Five cases were failed (0.5%). Intraprocedural complications included superficial injection in eight cases (0.8%). Acute and delayed onset of dyspnea was observed in three (0.3%) and two (0.2%) cases, respectively. The incidence of failures and major complications requiring active intervention was 1.6%. Conclusion: Our findings suggest that office-based CaHA injection laryngoplasty via the cricothyroid approach is as safe as conventional transoral injection laryngoplasty. Level of Evidence: 4. Laryngoscope, 2019.

Original languageEnglish
JournalLaryngoscope
DOIs
StatePublished - 1 Jan 2019

Fingerprint

Laryngoplasty
Durapatite
Calcium
Safety
Injections
Medical Records
Laryngoscopes
Dyspnea
Physicians
Incidence

Keywords

  • Complication
  • calcium hydroxylapatite
  • dyspnea
  • injection laryngoplasty
  • vocal fold paralysis

Cite this

@article{e1c92a5d67b148229a5e0d566b0446ea,
title = "Safety of office-based percutaneous injection laryngoplasty with calcium hydroxylapatite",
abstract = "Objective: To evaluate the safety of office-based calcium hydroxylapatite (CaHA) injection laryngoplasty via the cricothyroid approach through an analysis of all procedures performed over a period of 10 years at a single institution. Methods: In total, 962 office-based CaHA injection laryngoplasty via the cricothyroid approach procedures were performed by a single physician at our institution between 2007 and 2016. From these, 955 procedures performed in 617 patients were included in our analysis. The medical records of all 617 patients were retrospectively reviewed. We classified all procedure-related complications according to the time of onset. Complications that occurred during the procedure were considered intraprocedural complications, whereas complications that developed within 1 week after injection and those that developed after 1 week and were recorded more than twice in the medical records were considered acute and delayed complications, respectively. Failed cases were categorized separately as failure. Results: Five cases were failed (0.5{\%}). Intraprocedural complications included superficial injection in eight cases (0.8{\%}). Acute and delayed onset of dyspnea was observed in three (0.3{\%}) and two (0.2{\%}) cases, respectively. The incidence of failures and major complications requiring active intervention was 1.6{\%}. Conclusion: Our findings suggest that office-based CaHA injection laryngoplasty via the cricothyroid approach is as safe as conventional transoral injection laryngoplasty. Level of Evidence: 4. Laryngoscope, 2019.",
keywords = "Complication, calcium hydroxylapatite, dyspnea, injection laryngoplasty, vocal fold paralysis",
author = "Minhyung Lee and Lee, {Doh Young} and Tack-Kyun Kwon",
year = "2019",
month = "1",
day = "1",
doi = "10.1002/lary.27861",
language = "English",
journal = "Laryngoscope",
issn = "0023-852X",
publisher = "Wiley-Blackwell",

}

Safety of office-based percutaneous injection laryngoplasty with calcium hydroxylapatite. / Lee, Minhyung; Lee, Doh Young; Kwon, Tack-Kyun.

In: Laryngoscope, 01.01.2019.

Research output: Contribution to journalReview articleResearchpeer-review

TY - JOUR

T1 - Safety of office-based percutaneous injection laryngoplasty with calcium hydroxylapatite

AU - Lee, Minhyung

AU - Lee, Doh Young

AU - Kwon, Tack-Kyun

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Objective: To evaluate the safety of office-based calcium hydroxylapatite (CaHA) injection laryngoplasty via the cricothyroid approach through an analysis of all procedures performed over a period of 10 years at a single institution. Methods: In total, 962 office-based CaHA injection laryngoplasty via the cricothyroid approach procedures were performed by a single physician at our institution between 2007 and 2016. From these, 955 procedures performed in 617 patients were included in our analysis. The medical records of all 617 patients were retrospectively reviewed. We classified all procedure-related complications according to the time of onset. Complications that occurred during the procedure were considered intraprocedural complications, whereas complications that developed within 1 week after injection and those that developed after 1 week and were recorded more than twice in the medical records were considered acute and delayed complications, respectively. Failed cases were categorized separately as failure. Results: Five cases were failed (0.5%). Intraprocedural complications included superficial injection in eight cases (0.8%). Acute and delayed onset of dyspnea was observed in three (0.3%) and two (0.2%) cases, respectively. The incidence of failures and major complications requiring active intervention was 1.6%. Conclusion: Our findings suggest that office-based CaHA injection laryngoplasty via the cricothyroid approach is as safe as conventional transoral injection laryngoplasty. Level of Evidence: 4. Laryngoscope, 2019.

AB - Objective: To evaluate the safety of office-based calcium hydroxylapatite (CaHA) injection laryngoplasty via the cricothyroid approach through an analysis of all procedures performed over a period of 10 years at a single institution. Methods: In total, 962 office-based CaHA injection laryngoplasty via the cricothyroid approach procedures were performed by a single physician at our institution between 2007 and 2016. From these, 955 procedures performed in 617 patients were included in our analysis. The medical records of all 617 patients were retrospectively reviewed. We classified all procedure-related complications according to the time of onset. Complications that occurred during the procedure were considered intraprocedural complications, whereas complications that developed within 1 week after injection and those that developed after 1 week and were recorded more than twice in the medical records were considered acute and delayed complications, respectively. Failed cases were categorized separately as failure. Results: Five cases were failed (0.5%). Intraprocedural complications included superficial injection in eight cases (0.8%). Acute and delayed onset of dyspnea was observed in three (0.3%) and two (0.2%) cases, respectively. The incidence of failures and major complications requiring active intervention was 1.6%. Conclusion: Our findings suggest that office-based CaHA injection laryngoplasty via the cricothyroid approach is as safe as conventional transoral injection laryngoplasty. Level of Evidence: 4. Laryngoscope, 2019.

KW - Complication

KW - calcium hydroxylapatite

KW - dyspnea

KW - injection laryngoplasty

KW - vocal fold paralysis

UR - http://www.scopus.com/inward/record.url?scp=85061427686&partnerID=8YFLogxK

U2 - 10.1002/lary.27861

DO - 10.1002/lary.27861

M3 - Review article

JO - Laryngoscope

JF - Laryngoscope

SN - 0023-852X

ER -